Brain STimulation for Arm Recovery After Stroke 2

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Stroke

In brief

Rationale: Every year, about 40,000 people in the Netherlands have a stroke. After the initial admission to the hospital, about 15% of stroke survivors is admitted to a rehabilitation center because of remaining disabilities. Three out of four of these patients have upper limb dysfunction, hampering activities of daily living. Upper limb function plays a critical role in the performance of most daily life activities. In our phase II trial B-STARS, continuous theta burst stimulation (cTBS) treatment led to an absolute additional recovery of upper limb function of 17%, as measured with the Action Research Arm Test (ARAT) score three months after stroke. This improvement exceeds the minimal clinically important difference of 10%. cTBS treatment also resulted in a significant improvement in measures of activities and participation (of similar magnitude) and a reduction in the mean length of stay at the rehabilitation center by 18 days. Objective: To assess the effectiveness and cost effectiveness of cTBS treatment in promoting upper limb recovery after stroke in patients admitted to a rehabilitation center. Study design: A phase III, multi-center, double-blind, randomized, sham-controlled, clinical trial. Study population: 454 patients aged 18 years or older with a first-ever ischemic stroke or intracerebral hemorrhage and a unilateral arm paresis, defined by a Motricity Index between 9 and 99, in whom cTBS treatment can be started within 3 weeks after stroke onset. Intervention: 10 daily sessions of cTBS delivered over the contralesional primary motor cortex during a period of 2 weeks, delivered immediately before regular care physical therapy of the affected upper limb. Main study parameters/endpoints: The primary endpoint will be the score on the upper extremity section of the Fugl-Meyer assessment (FM-UE) at 90 days after stroke. Secondary endpoints will include the score on the FM-UE at one year and the scores on the Action Research Arm Test, Nine Hole Peg Test, Stroke Impact Scale, EuroQol 5 Dimensions and modified Rankin Scale at 90 days and one year after stroke

Key facts

Study ID

NCT06265766

Run by

Jord Vink

People needed

454

Starts

2024-12-09

Expected to finish

2029-12-31

Last updated by the study team

2025-08-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age, 18 years or older
• First-ever unilateral ischemic stroke or intracerebral hemorrhage in a cerebral hemisphere or the brainstem;
• Unilateral upper limb paresis with a motricity index between 9 and 99;
• Possibility to start cTBS treatment within 21 days after stroke onset;
• Signed informed consent.

You may not qualify if…

• Upper limb paresis prior to stroke onset;
• Absolute contra-indication to TMS
• Magnetic sensitive objects implanted in the head or neck area (e.g. cochlear implants, implanted neurostimulator, pacemaker or defibrillator, metal splinters, metal fragments or metal clips);
• History of epilepsy;
• Other contra-indications that may potentially be harmful as determined by the treating rehabilitation physician;
• Severe impairments that can impede study participation as determined by the treating rehabilitation physician (i.e. extreme fatigue, severe communication deficits);
• Life expectancy shorter than one year.

Where it is running

• Vogellanden — Zwolle, Netherlands (enrolling)
• Reade — Amsterdam, Netherlands (enrolling)
• Revalidatie Friesland — Beetsterzwaag, Netherlands (enrolling)
• Revant — Breda, Netherlands (enrolling)
• Libra Leijpark — Tilburg, Netherlands (enrolling)
• De Hoogstraat — Utrecht, Netherlands (enrolling)
• Heliomare — Wijk aan Zee, Netherlands (enrolling)
• Libra Blixembosch — Eindhoven, Netherlands (enrolling)
• Merem — Hilversum, Netherlands (enrolling)
• Adelante — Hoensbroek, Netherlands (enrolling)
• Basalt — Leiden, Netherlands (enrolling)
• Sint Maartenskliniek — Nijmegen, Netherlands (enrolling)
• Basalt — The Hague, Netherlands (enrolling)
• MRC Aardenburg — Doorn, Netherlands
• Tolbrug — 's-Hertogenbosch, Netherlands
• University Medical Center Groningen — Groesbeek, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.